Conference Reports for NATAP

HIVR4P 2024 5th HIV Research for Prevention Conference Lima, Peru - Oct 6-10 2024 Back

Tweet

Gilead Lenacapavir Access Statement & Voluntary Licensing Agreement       Recent press release about voluntary licensing agreements:https://www.gilead.com/news/news-details/2024/gilead-signs-royalty-free-voluntary-licensing-agreements-with-six-generic-manufacturers-to-increase-access-to-lenacapavir-for-hiv-prevention-in-high-incidence-resource-limited-countries   Gilead's access statement: https://www.gilead.com/company/company-statements/2024/updated-statement-on-access-planning-in-high-incidence-resource-limited-countries-for-lenacapavir-for-hiv-prevention